About Septerna Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR ...

Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the ...

Novo Nordisk (NVO) shares fell over 15% on Monday after the company’s next-generation obesity drug CagriSema delivered less weight loss than Eli Lilly’s (LLY) competing treatment in a phase 3 trial, ...

Novo Nordisk stock dived after Novo's next-generation obesity drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. Lilly stock rose.

Peer-reviewed study characterizes in vitro and ex vivo activities of novel antibody agonists generated using Abalone ...

New Cell-Based Assay Supports Drug Discovery Targeting Appetite Regulation, Stress Biology, and Autonomic Function ...

Nxera believes this is the best approach to maximise the value of the receptor program and enable it to reach patients. Nxera may also choose to participate in a Series A financing round of NewCo in ...

Meridian Funds, managed by ArrowMark Partners, released its fourth-quarter 2025 investor letter for “Meridian Small Cap ...

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

Detailed price information for Structure Therapeutics Inc (GPCR-Q) from The Globe and Mail including charting and trades.

Researchers analyzed the thermodynamics of doxepin binding to the histamine H1 receptor. The findings highlight the importance of enthalpy and entropy in GPCR drug design and provide guidance for the ...

Nxera Pharma has moved to cut performance-linked remuneration for its top executives following the release of its full-year 2025 financial results. The company said it aims to underscore disciplined ...